Enochian

Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer

Retrieved on: 
Thursday, April 7, 2022
NASDAQ, Leadership, Cancer, CEO, Senior, Trial of the century, Pfizer, Data management, Â, GLOBE, Science, Operation, List, Infection, Pharmaceutical industry, Enochian

LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer.

Key Points: 
  • LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer.
  • Since 2016, he has served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader.
  • During his time at Pfizer, Greg took on increasing levels of leadership across a broad range of functions within the Clinical Operations space including Clinical Project Management, Study Management, Project Planning, Statistical Programming and Data Management.
  • I was very impressed by the science, project management and planning for clinical trials and commercialization of Enochian BioSciences, Greg said.

Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit

Retrieved on: 
Tuesday, April 5, 2022
Company, Glioblastoma, NASDAQ, Summit, SEC, B cell, DC, Neoplasm, Natural killer T cell, Cancer, CEO, Immune system, Technology, Intellectual property, GLOBE, HIV, UCLA, NK, Nature, Annual report, FDA, Blood, List, Infection, Vaccine, Medical device, Enochian

Dr. Gumrukus scientific presentation focused on innovative clinical strategies he has designed to hyper-stimulate various components of the immune system, including those that are part of innate killer immunity.

Key Points: 
  • Dr. Gumrukus scientific presentation focused on innovative clinical strategies he has designed to hyper-stimulate various components of the immune system, including those that are part of innate killer immunity.
  • Dr. Gumruku has completed an FDA pre-IND meeting and is in the process of preparing an Investigator Initiated IND.
  • Dr. Mark Dybul, the CEO of Enochian BioSciences said, I believe it was fitting for the Summit organizers to recognize the brilliant scientific ideas of Dr. Gumruku.
  • Enochian BioSciences looks forward to advancing as many of them as possible, potentially saving many, many lives.

Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans

Retrieved on: 
Tuesday, March 15, 2022
SEC, Human, Technology, GLOBE, Sickle cell disease, List, University, Annual report, San Francisco, Patient, HIV/AIDS, Influenza, Executive, Hepatitis B, Nature, US Food Sovereignty Alliance, California Institute for Regenerative Medicine, NASDAQ, Clinical trial, Food, Science Translational Medicine, Regenerative medicine, Cancer, CEO, HIV, Phase, University of California, Davis, University of California, San Francisco, Infection, Thalassemia, Pharmaceutical industry, Vaccine, Enochian, Oncology

Caring Cross is an innovative non-profit that partners with others, including for-profit companies, to increase access to new technologies and medicines under a collaborative value sharing model.

Key Points: 
  • Caring Cross is an innovative non-profit that partners with others, including for-profit companies, to increase access to new technologies and medicines under a collaborative value sharing model.
  • Caring Cross and Enochian BioSciences entered into a profit-sharing agreement as part of the sub-license.
  • The CAR-T approach being studied in humans was shown to cure HIV infection in an animal model that was published in the prestigious scientific journal, Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.aav56850).
  • Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy.

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

Retrieved on: 
Tuesday, July 20, 2021
Linguistics, Language, Enochian magic, Alphabets, Enochian

has been named as Chief Executive Officer (CEO).

Key Points: 
  • has been named as Chief Executive Officer (CEO).
  • Dr. Dybul, who has served as Executive Vice-Chair of the Board of Enochian BioSciences since January 2019, is a globally recognized leader in pandemics.
  • It is a great privilege to have one of the worlds preeminent public health experts assume the role of CEO of Enochian BioSciences, said Enochian BioSciences Chair of the Board Ren Sindlev.
  • Marks deep expertise in science, combined with his long experience managing research programs and advising on strategy, brings key and difficult-to-find competencies to Enochian BioSciences.

Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Monday, February 22, 2021
Linguistics, Life sciences, Articles, Biotechnology, Alphabets, Enochian, Enochian magic, Biopharmaceutical, Linguistics, Life sciences, Articles, Biotechnology, Alphabets, Enochian, Enochian magic, Biopharmaceutical

LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.

Key Points: 
  • LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences , a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
  • The presentation will be available on-demand for conference attendees beginning at 7 am Eastern on Tuesday, March 9, 2021, and also will be available on the Enochian BioSciences website under the Investors/Media section in Events and Presentations .
  • On March 10, Dr. Dybul and Chief Financial Officer Luisa Puche will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conference.
  • Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy.

Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

Retrieved on: 
Monday, July 27, 2020
Linguistics, Language, Hepatitis D, Riboviria, Enochian

Dr. Brosgart joined the Board of Directors of Enochian BioSciences in January, 2020.

Key Points: 
  • Dr. Brosgart joined the Board of Directors of Enochian BioSciences in January, 2020.
  • The approach Enochian BioSciences has to a potential HBV treatment or cure exploits an innovative pathway that is novel in the field, said Dr. Zoulim.
  • I was particularly impressed by the rapid progress Enochian BioSciences has made in such a short period of time.
  • Dr. Revill said: I was extremely impressed with Enochian BioSciences presentation on its HBV approach and research at the recent HEP DART meeting.